Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

itric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).

http://www.nicox.com


'/>"/>
SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... astronaut Scott Kelly , who is making final preparations ... and working on the International Space Station, will be available ... Monday, March 9. Kelly will participate from ... of his training. The interviews will be preceded at 5 ... training and previous spaceflights. To schedule an interview, ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... to a biotech company (it is priority #1, #2, and ... sense) companies are continually faced with the challenge of raising ... article will focus on venture capital financing results for 2005. ... from Burrill and Company's data. Burrill's perspective is more towards ...
... before I get all lathered up about the latest outrages ... recognize completely that the majority of top executives are honest ... to success. And that the CEO's I will be talking ... are people who work the system to their great benefit ...
... statewide, is holding information sessions for parents until the end ... ,Children enrolled in the academy are lent a computer, monitor, ... home with a parent or other responsible adult and correspond ... Since it's a public school, there is no tuition. , ...
Cached Biology Technology:U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4What color is your CEO's parachute? 2What color is your CEO's parachute? 3What color is your CEO's parachute? 4
(Date:2/5/2015)... , January 28, 2015 New ... Size And Segment Forecasts To 2020 has Been Added ... camera market is expected to reach USD 5.10 billion ... View Research, Inc. IR cameras help identify the site ... expected to witness surging demand in medical imaging applications. ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... therapy often harms healthy tissue as it tries to kill ... Department of Biomedical Engineering is developing a new way to ... surrounding tissue. His innovative method, soon to be ... kill the tumor cells but leaves surrounding healthy tissue intact. ...
... a leading cause of mortality worldwide, accounting for more than ... expected to exceed 12 million. The ESMO Congress provides a ... the treatment of cancer Congress Program Highlights ... potentially practice changing, Promising new drugs to treat ovarian, skin, ...
... Under the microscope, the bacteria start dividing normally, two ... then individual cells begin "popping," like circus balloons being struck ... bioengineers who captured it on video, turns out to be ... considered by scientists creating living, synthetic circuits out of bacteria. ...
Cached Biology News:A 'magnetic' solution to identify and kill tumors 235th ESMO Congress media alert 235th ESMO Congress media alert 3Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Complement factor B (human)...
... NH2-terminal kinase) signal transduction cascade is ... pathways in mammals. JNK pathway activation ... is associated with the nuclear accumulation ... in the immune response, cellular proliferation, ...
... near- and far-infrared range FT-IR spectrometers give ... their class. Yet all this comes at ... throughput: Having a larger and faster ... other conventional FT-IRs provides 300%,larger solid angle ...
Biology Products: